Editas Medicine Inc (NASDAQ:EDIT)

41.06
BATS BZX Real-Time Price
As of 10:50am ET
 +1.54 / +3.90%
Today’s Change
21.41
Today|||52-Week Range
99.95
-41.43%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$2.7B

Company Description

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Contact Information

Editas Medicine, Inc.
11 Hurley Street
Cambridge Massachusetts 02141
P:(617) 401-9000
Investor Relations:

Employees

Shareholders

Mutual fund holders49.85%
Individual stakeholders27.59%
Other institutional24.57%

Top Executives

James C. MullenChairman, President & Chief Executive Officer
Harry R. GillSenior Vice President-Operations
Michelle RobertsonTreasurer, Chief Financial & Accounting Officer
Lisa A. MichaelsChief Medical Officer & Executive Vice President
David LitvakDirector-Technical Operations